PSTV Quote, Financials, Valuation and Earnings

Retractable Technologies has a net margin of -- compared to Plus Therapeutics's net margin of -18.58%. Plus Therapeutics's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

Plus Therapeutics has a consensus price target of $9.38, signalling upside risk potential of 708.19%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Plus Therapeutics has higher upside potential than Retractable Technologies, analysts believe Plus Therapeutics is more attractive than Retractable Technologies.

Plus Therapeutics has a beta of 0.734, which suggesting that the stock is 26.621% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.083, suggesting its more volatile than the S&P 500 by 108.265%.

Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

Plus Therapeutics quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Plus Therapeutics's net income of -$2.9M is lower than Retractable Technologies's net income of -$1.9M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 1.27x versus 0.55x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -- compared to Plus Therapeutics's net margin of -1226.82%. Plus Therapeutics's return on equity of -- beat VolitionRX's return on equity of --.

Plus Therapeutics has a consensus price target of $9.38, signalling upside risk potential of 708.19%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 513.33%. Given that Plus Therapeutics has higher upside potential than VolitionRX, analysts believe Plus Therapeutics is more attractive than VolitionRX.

Plus Therapeutics has a beta of 0.734, which suggesting that the stock is 26.621% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Plus Therapeutics quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $474.5K. Plus Therapeutics's net income of -$2.9M is higher than VolitionRX's net income of -$5.8M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 1.27x versus 35.50x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -- compared to Plus Therapeutics's net margin of -4291.67%. Plus Therapeutics's return on equity of -- beat Catheter Precision's return on equity of -65.84%.

Plus Therapeutics has a consensus price target of $9.38, signalling upside risk potential of 708.19%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 463.86%. Given that Plus Therapeutics has higher upside potential than Catheter Precision, analysts believe Plus Therapeutics is more attractive than Catheter Precision.

Plus Therapeutics has a beta of 0.734, which suggesting that the stock is 26.621% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.541, suggesting its less volatile than the S&P 500 by 154.132%.

Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Plus Therapeutics quarterly revenues are --, which are smaller than Catheter Precision quarterly revenues of $96K. Plus Therapeutics's net income of -$2.9M is higher than Catheter Precision's net income of -$4.1M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 1.27x versus 0.95x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Plus Therapeutics's net margin of -10.04%. Plus Therapeutics's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.34%.

Plus Therapeutics has a consensus price target of $9.38, signalling upside risk potential of 708.19%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 257.58%. Given that Plus Therapeutics has higher upside potential than Xtant Medical Holdings, analysts believe Plus Therapeutics is more attractive than Xtant Medical Holdings.

Plus Therapeutics has a beta of 0.734, which suggesting that the stock is 26.621% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Plus Therapeutics quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Plus Therapeutics's net income of -$2.9M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 1.27x versus 0.56x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.